Breo Ellipta 25 ug/1

Breo Ellipta 25 ug/1 is a respiratory medication combining fluticasone furoate and vilanterol trifenatate. It is designed for inhalation use to manage chronic respiratory conditions. This powder-based inhaler is manufactured by GlaxoSmithKline LLC in the USA.

Breo Ellipta 25 ug/1 is primarily used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma. The combination of fluticasone furoate, a corticosteroid, and vilanterol trifenatate, a long-acting beta-agonist, works to reduce inflammation and improve airflow in the lungs. This medication is often prescribed to individuals who require both an anti-inflammatory and a bronchodilator for effective respiratory management.

Common effects of Breo Ellipta 25 ug/1 may include throat irritation, headache, and hoarseness. Some users might experience a dry mouth or cough. These effects are generally mild and temporary, but if they persist or worsen, it is advisable to consult a healthcare professional.

Breo Ellipta 25 ug/1 should be used as directed by a healthcare provider. It is important to follow the prescribed dosage and administration instructions. Patients with a history of severe hypersensitivity to any of the components should avoid using this medication. Regular monitoring and follow-up are recommended to ensure the medication's effectiveness and safety.

Breo Ellipta 25 ug/1 may interact with other medications, including beta-blockers, diuretics, and certain antidepressants. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Additionally, the use of alcohol or other respiratory depressants should be discussed with a healthcare professional.